Role of lipid-soluble complexes in targeted tumor therapy

Journal of Nuclear Medicine

Volumn 44, Issue 8, 2003, Pages 1293-1300

  Thakur, Mathew L ^a,d   Coss, Ron ^a   Howell, Roger ^b   Vassileva Belnikolovska, Donka ^c   Liu, Jeff ^a   Rao, Sampath P ^a   Spana, Greg ^a   Wachsberger, Phyllis ^a   Leeper, Dennis L ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^c Natl Ctr Clin Transfusional H   (Bulgaria)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Targeted radionuclide therapy

Indexed keywords

8 QUINOLINOL INDIUM IN 111; LUTETIUM; MERCAPTOPYRIDINE N OXIDE IN 111; PYRIDINE DERIVATIVE; RADIOISOTOPE; UNCLASSIFIED DRUG; YTTRIUM 90; 8 QUINOLINOL; 8 QUINOLINOL INDIUM; DRUG DERIVATIVE; LIPID; ORGANOMETALLIC COMPOUND; PYRITHIONE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUGER ELECTRON SPECTROSCOPY; AUTORADIOGRAPHY; BLOOD SAMPLING; BODY WEIGHT; BREAST CANCER; CARCASS; CELL COUNT; CELL HYPOXIA; COLORECTAL CANCER; CONTROLLED STUDY; CYTOPLASM; DOSIMETRY; DRUG TISSUE LEVEL; FEASIBILITY STUDY; INTERMETHOD COMPARISON; KIDNEY; LIVER; MOLECULAR WEIGHT; MOUSE; NEUTROPHIL; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RADIATION DOSE; SAFETY; STATISTICAL ANALYSIS; THEORETICAL STUDY; TISSUE SECTION; TUMOR GROWTH; TUMOR VOLUME; X RAY; ANIMAL; BREAST TUMOR; CELL CULTURE; CELL LINE; CHEMISTRY; COLORECTAL TUMOR; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; EVALUATION; HUMAN; INTRALESIONAL DRUG ADMINISTRATION; MALE; METABOLISM; METHODOLOGY; NEOPLASM; NUDE MOUSE; PROSTATE TUMOR; RADIATION RESPONSE; SCINTISCANNING; SOLUBILITY; TREATMENT OUTCOME;

ANIMALS; BREAST NEOPLASMS; CELL LINE; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG DELIVERY SYSTEMS; FEASIBILITY STUDIES; HUMANS; INJECTIONS, INTRALESIONAL; LIPIDS; MALE; MICE; MICE, NUDE; NEOPLASMS; ORGANOMETALLIC COMPOUNDS; OXYQUINOLINE; PROSTATIC NEOPLASMS; PYRIDINES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; SOLUBILITY; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0141781295     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Brady LJ, Levit SH. Future directions of imaging research: subspecialty society messages. Radiology. 1998;209:593-596
2. Sandler HM. Prostate cancer: patient's dilemma? Cancer J Sci Am 1998;4:347-348.
3. 125I prostate implant followed by external-beam radiation Cancer J Sci Am. 1998;4:359-363.
4. McLaughlin PW, Narayana V, Fields MT, et al. Permanent implantation of I-125 sources in the prostate: radical limits of simplicity. Radiology. 1999;213:839-844.
5. Fortin A, Larochelle M, Laverdiere J, et al Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy. J Clin Oncol. 1999;17:101-109.
6. Thakur ML, Coleman RE, Welch MJ. Indium-111-labeled leukocytes for the localization of abscesses: preparation, analysis, tissue distribution, and comparison with gallium-67 citrate in dogs. J Lab Clin Med. 1977;89:217-228.
7. Thakur ML, McKenney SL, Park CH. Simplified and efficient labeling of human platelets in plasma using indium-111-2-mercaptopyridine-N-oxide: preparation and evaluation. J Nucl Med. 1985;26:510-517.
8. Thakur ML, McKenney SL, Park CH. Evaluation of indium-111-2- mercaptopyridine-N-oxide for labeling leukocytes in plasma: a kit preparation. J Nucl Med. 1985;26:518-523.
9. Thakur ML, Segal AW, Louis L, et al. Indium-111-labeled cellular blood components: mechanism of labeling and intracellular location in human neutrophils. J Nucl Med. 1977;18:1022-1029.
10. 111In and mercaptopyridine-N-oxide. J Lab Clin Med. 1986;107:141-147.
11. Thakur ML, Lavender JP, Arnot RN, et al. Indium-111-labeled autologous leukocytes in man. J Nucl Med. 1977;18:1014-1021.
12. Thakur ML, Walsh L, Malech HL, et al. Indium-111-labeled human platelets: improved method, efficacy, and evaluation. J Nucl Med. 1981;22:381-385.
13. Lavender JP, Goldman JM, Arnot RN, Thakur ML. Kinetics of indium-111 labeled lymphocytes in normal subjects and patients with Hodgkin's disease Br Med J. 1977;2:797-799.
14. Thakur ML, Welch MJ, Joist H, et al. Indium-111 labeled platelets: studies on preparation and evaluation of in vitro and in vivo functions. Thromb Res. 1976;9:345-357
15. Muul LM, Nason-Burchenal K, Carter CS, et al Development of an automated closed system for generation of human lymphokine-activated killer. J Immunol Methods. 1987;101:171-181.
16. Rosenberg SA, Lotze MT, Muul LM, et al. A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2. Surgery. 1986;100 262-272.
17. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activaied killer cells and interleukin-2 or high-dose interleukin-2 alone N Engl J Med 1987;316:889-897.
18. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res. 1999;59:56-58.
19. Eggert AAO, Schreurs MWJ, Boerman OC, et al Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res. 1999;59:3340-3345.
20. ten Berge RJM, Natarajan AT, Hardeman MR, et al. Labeling with indium-111 has detrimental effects on human lymphocytes: concise communication. J Nucl Med. 1983,24:615-620.
21. 111In in mammalian cells in vitro. Radiat Res. 1989;119:205-210.
22. Thakur ML, McAfee JG. The significance of chromosomal aberrations in indium-111 labeled lymphocytes. J Nucl Med 1984,25:922-927.
23. Rao DV, Sastry KSR, Grimmond HE, et al. Cytotoxicity of some indium radiopharmaceuticals in mouse testes J Nucl Med. 1988;29:375-384
24. Horton HM, Hernandez P, Parker SE, et al. Antitumor effect of interferon-ω: in vivo therapy of human tumor xenografts in nude mice. Cancer Res. 1999,59: 4064-4068.
25. Mohan PM, Chintala SK, Mohanam S, et al Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth. Cancer Res. 1999;59:3369-3373.
26. Silvester DJ. Consequences of indium-111 decay in vivo: calculated absorbed radiation dose to cells labeled by indium-111-oxine. J Labelled Compds Radiopharm. 1978;19:196-197.
27. Goddu SM, Rao DV, Howell RW. Multicellular dosimetry for micrometastases: dependence of self-dose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides J Nucl Med. 1994;35:521-530.
28. Howell RW. Radiation spectra for Auger electron emitting radionuclides: Report No. 2 of AAPM Nuclear Medicine Task Group No 6. Med Phys. 1992;19:1371-1383
29. Hubbel JH. Photon mass attenuation and energy absorption coefficients from 1 keV to 20 MeV. Int J Appl Radiat Isot. 1982;33:1269-1290.
30. Howell RW, Rao DV, Sastry KSR. Macroscopic dosimetry for radioimmunotherapy: nonuniform activity distributions in solid tumors. Med Phys. 1989;16: 66-74.
31. Eckerman KF, Westfall RJ, Ryman JC, Cristy M. Nuclear Decay Data Files of the Dosimetry Research Group. ORNI/TM-12350. Knoxville, TN: Oak Ridge National Laboratory; 1993.
32. ICRU. Stopping Powers for Electrons and Positrons. Report 37. Bethesda, MD: International Commission on Radiation Units and Measurements; 1984
33. Goddu SM, Howell RW, Rao DV A generalized approach to absorbed dose calculations for dynamic tumor and organ masses. J Nucl Med. 1995;36:1923-1927.
34. Howell RW, Narra VR, Rao DV Absorbed dose calculations for rapidly growing tumors. J Nucl Med. 1992;33:277-281
35. Waterman FM, Yue N, Corn BW, Dicker AP Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: an analysis based on serial CT acquisition. Int J Radiat Oncol Biol Phys. 1999;43: 447-454.
36. 111In-pentreotide: initial observations and future directions. Cancer J Sci Am. 1998;4:94-102.
37. 1]-Octreotide. a case history. Ann N Y Acad Sci. 1993;733:496-506.